Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep804 | Pituitary: clinical | ECE2015

Pharmacokinetic and pharmacodynamic analyses of pasireotide LAR from a randomised, phase III study in patients with inadequately controlled acromegaly

Shen Guoxiang , Darstein Christelle , Resendiz Karina Hermosillo , Hu Ke

Introduction: A 24-week, PhIII, randomised study (PAOLA) demonstrated superior efficacy of pasireotide long-acting release (PAS-LAR; 40 and 60 mg) vs continued treatment with octreotide LAR 30 mg or lanreotide Autogel 120 mg (15.4%, 20.0% vs 0%) at providing biochemical control (GH<2.5 μg/l and normalized IGF-1) in patients with acromegaly inadequately controlled on first-generation somatostatin analogues. Results from PK/PD analyses of PAS-LAR are reported here.<...